Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
Agostinetto E, Pfeiler G, Hlauschek D, Mayer EL, Lambertini M, de Azambuja E, Bellet-Ezquerra M, Meisel JL, Rubovszky G, Zdenkowski N, Novik Y, Ruiz-Borrego M, Gelmon KA, Mamounas EP, Iwata H, Lu DR, Soelkner L, Fesl C, Gnant M, DeMichele A. Agostinetto E, et al. Among authors: lambertini m. ESMO Open. 2025 Jan 3;10(1):104096. doi: 10.1016/j.esmoop.2024.104096. Online ahead of print. ESMO Open. 2025. PMID: 39754986 Free article.
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.
Schettini F, Nucera S, Pascual T, Martínez-Sáez O, Sánchez-Bayona R, Conte B, Buono G, Lambertini M, Punie K, Cejalvo JM, Arpino G, Vigneri P, Generali D, Ciruelos E, Cortés J, Gennari A, Muñoz M, Vidal Losada MJ, Tolaney SM, Prat A, Villacampa G. Schettini F, et al. Among authors: lambertini m. Cancer Treat Rev. 2025 Jan;132:102865. doi: 10.1016/j.ctrv.2024.102865. Epub 2024 Dec 19. Cancer Treat Rev. 2025. PMID: 39709655 Free article. Review.
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial.
Meattini I, De Santis MC, Visani L, Scorsetti M, Fozza A, Meduri B, De Rose F, Bonzano E, Prisco A, Masiello V, La Rocca E, Spoto R, Becherini C, Blandino G, Moscetti L, Colciago RR, Audisio RA, Brain E, Caini S, Hamaker M, Kaidar-Person O, Lambertini M, Marrazzo L, Saieva C, Spanic T, Strnad V, Wheelwright S, Poortmans PMP, Livi L; EUROPA Trial Investigators. Meattini I, et al. Among authors: lambertini m. Lancet Oncol. 2025 Jan;26(1):37-50. doi: 10.1016/S1470-2045(24)00661-2. Epub 2024 Dec 12. Lancet Oncol. 2025. PMID: 39675376 Clinical Trial.
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study.
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L. Molinelli C, et al. Among authors: lambertini m. Eur J Cancer. 2024 Dec;213:115113. doi: 10.1016/j.ejca.2024.115113. Epub 2024 Nov 4. Eur J Cancer. 2024. PMID: 39536433 Free article.
468 results